文献速递冠心病血脂与心血管预防

糖尿病与非糖尿病患者中iFR与FFR指导策略的主要不良心脏事件比较:随机临床试验二次分析

Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2019-01-01

DEFINE-FLAIR试验二次分析纳入2492例中度冠脉狭窄患者,其中758例(30.4%)合并糖尿病。1年时糖尿病患者MACE发生率显著高于非糖尿病患者(8.6% vs 5.6%;校正HR 1.88;95%CI 1.28-2.64;P<.001),但iFR与FFR指导组在糖尿病和非糖尿病亚组中MACE风险均无显著差异。

要点

  • 糖尿病患者1年MACE风险显著高于非糖尿病患者(8.6% vs 5.6%;校正HR 1.88;P<.001)。
  • 糖尿病亚组中iFR与FFR指导的MACE风险无显著差异(10.0% vs 7.2%;校正HR 1.33;95%CI 0.78-2.25;P=.30)。
  • iFR与FFR指导在糖尿病患者中选择血运重建靶点具有同等安全性。

核心结论

  • 糖尿病患者MACE风险显著高于非糖尿病患者,无论采用iFR还是FFR指导。
  • iFR指导与FFR指导在糖尿病患者中MACE风险相当,选择血运重建靶点的安全性等同。

研究设计与样本

  • DEFINE-FLAIR试验为多中心、国际、随机、双盲试验,1:1随机分配2492例患者至iFR指导或FFR指导的冠脉血运重建。
  • 纳入标准为至少1支原生冠脉存在中度狭窄(直径狭窄40%-70%)。
  • iFR≤0.89和FFR≤0.80作为血运重建标准,高于阈值则推迟血运重建。

主要发现

  • 总人群中758例(30.4%)患有糖尿病,平均年龄66岁,76%为男性(1868/2465),80%表现为稳定型心绞痛(1983/2465)。
  • 非糖尿病亚组中,iFR指导组推迟血运重建率显著高于FFR指导组(56.5% [477/844] vs 46.6% [402/863];P<.001);糖尿病亚组中两组无差异(42.1% [161/382] vs 47.1% [177/376];P=.15)。
  • 1年时糖尿病组MACE发生率显著高于非糖尿病组(8.6% vs 5.6%;校正HR 1.88;95%CI 1.28-2.64;P<.001)。
  • 糖尿病亚组中iFR与FFR指导组MACE无显著差异(10.0% vs 7.2%;校正HR 1.33;95%CI 0.78-2.25;P=.30);非糖尿病亚组亦无差异(4.7% vs 6.4%;HR 0.83;95%CI 0.51-1.35;P=.45);交互作用P=.25。

关键数值与推荐

  • iFR≤0.89和FFR≤0.80作为血运重建标准。
  • 主要终点为1年主要不良心脏事件(MACE),定义为全因死亡、非致死性心肌梗死或非计划血运重建的复合终点。

临床怎么用

  • 对于合并2型糖尿病的中度冠脉狭窄患者,iFR或FFR指导的血运重建决策均可安全使用。
  • 糖尿病患者即使接受生理学指标指导的血运重建,仍面临显著高于非糖尿病患者的1年MACE风险,需加强危险因素管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Invasive physiologic indices such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are used in clinical practice. Nevertheless, comparative prognostic outcomes of iFR-guided and FFR-guided treatment in patients with type 2 diabetes have not yet been fully investigated. OBJECTIVE: To compare 1-year clinical outcomes of iFR-guided or FFR-guided treatment in patients with and without diabetes in the Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization (DEFINE-FLAIR) trial. DESIGN, SETTING, AND PARTICIPANTS: The DEFINE-FLAIR trial is a multicenter, international, randomized, double-blinded trial that randomly assigned 2492 patients in a 1:1 ratio to undergo either iFR-guided or FFR-guided coronary revascularization. Patients were eligible for trial inclusion if they had intermediate coronary artery disease (40%-70% diameter stenosis) in at least 1 native coronary artery. Data were analyzed between January 2014 and December 2015. INTERVENTIONS: According to the study protocol, iFR of 0.89 or less and FFR of 0.80 or less were used as criteria for revascularization. When iFR or FFR was higher than the prespecified threshold, revascularization was deferred. MAIN OUTCOMES AND MEASURES: The primary end point was major adverse cardiac events (MACE), defined as the composite of all-cause death, nonfatal myocardial infarction, or unplanned revascularization at 1 year. The incidence of MACE was compared according to the presence of diabetes in iFR-guided and FFR-guided groups. RESULTS: Among the total trial population (2492 patients), 758 patients (30.4%) had diabetes. Mean age of the patients was 66 years, 76% were men (1868 of 2465), and 80% of patients presented with stable angina (1983 of 2465). In the nondiabetes population (68.5%; 1707 patients), iFR guidance was associated with a significantly higher rate of deferral of revascularization than the FFR-guided group (56.5% [n = 477 of 844] vs 46.6% [n = 402 of 863]; P < .001). However, it was not different between the 2 groups in the diabetes population (42.1% [n = 161 of 382] vs 47.1% [n = 177 of 376]; P = .15). At 1 year, the diabetes population showed a significantly higher rate of MACE than the nondiabetes population (8.6% vs 5.6%; adjusted hazard ratio [HR], 1.88; 95% CI, 1.28-2.64; P < .001). However, there was no significant difference in MACE rates between iFR-guided and FFR-guided groups in both the diabetes (10.0% vs 7.2%; adjusted HR, 1.33; 95% CI, 0.78-2.25; P = .30) and nondiabetes population (4.7% vs 6.4%; HR, 0.83; 95% CI, 0.51-1.35; P = .45) (interaction P = .25). CONCLUSIONS AND RELEVANCE: The diabetes population showed significantly higher risk of MACE than the nondiabetes population, even with the iFR-guided or FFR-guided treatment. The iFR-guided and FFR-guided treatment showed comparable risk of MACE and provided equal safety in selecting revascularization target among patients with diabetes. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02053038.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee JM, Choi KH, Koo BK, et al. Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019. PMID: 31314045. doi:10.1001/jamacardio.2019.2298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。